REVIEW article
Front. Pharmacol.
Sec. Inflammation Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1660890
Advances in Drug Delivery Systems for the Management of Gou t and Hyperuricemia
Provisionally accepted
Zining Peng1,2
Fanyu Meng1
Qian Deng1Yuanbo Huang1Danning Mao1Yuan Long1
Yan Weitian2Jiangyun Peng2*
Xingqiang Wang2*
Nian Liu1,2*- 1Yunnan University of Traditional Chinese Medicine, Kunming, China
- 2Yunnan Provincial Hospital of Chinese Medicine, Kunming, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Gout and hyperuricemia represent significant global health burdens, characterized by painful inflammatory arthritis and systemic metabolic dysfunction, respectively. Current pharmacological management faces substantial limitations, including poor bioavailability, systemic toxicity, narrow therapeutic indices, immunogenicity, and suboptimal patient adherence due to frequent dosing and adverse effects. These challenges underscore the critical need for innovative therapeutic strategies. Advanced drug delivery systems (DDS) have emerged as transformative solutions to overcome these hurdles. This comprehensive review critically analyzes the latest advancements in DDS tailored for gout and hyperuricemia management. We first elucidate the intricate pathophysiological mechanisms linking hyperuricemia, monosodium urate crystal deposition, NLRP3 inflammasome activation, and chronic inflammation. We then systematically explore cutting-edge DDS platforms, including lipid-based, polymer-based, and other systems. These engineered drug delivery systems significantly enhance therapeutic outcomes in gout and hyperuricemia by improving drug solubility, enabling targeted delivery, providing sustained release, facilitating synergistic drug co-delivery, and responding to pathological microenvironments, but with limited preclinical evidence and sparse clinical evidence supporting their efficacy and safety. Finally, we highlights translational challenges and future directions while emphasizing the considerable promise of integrating AI, biomaterials science, and personalized medicine to advance patient-centric DDS. While progress has been made, sustained interdisciplinary collaboration and rigorous clinical validation remain critical to translate these innovations into tangible improvements in long-term disease management and quality of life for patients with gout and hyperuricemia.
Keywords: Gout, Hyperuricemia, Drug Delivery Systems, therapeutic, Prospect
Received: 08 Jul 2025; Accepted: 04 Sep 2025.
Copyright: © 2025 Peng, Meng, Deng, Huang, Mao, Long, Weitian, Peng, Wang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jiangyun Peng, Yunnan Provincial Hospital of Chinese Medicine, Kunming, China
Xingqiang Wang, Yunnan Provincial Hospital of Chinese Medicine, Kunming, China
Nian Liu, Yunnan University of Traditional Chinese Medicine, Kunming, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.